Odaberite jezik

hr
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Hrvatski
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Koja nadoplata na račun vam bolje odgovara?

* Ne naplaćujemo proviziju za polaganje depozita na vaš račun

Biogen

BIIB.US $ 279.89 USD

-6.28 $ (-2.21%)

Potencijal rasta

3.53%

Prihod od dividende

1d
1t
1 mj.
6 mjes.
Cijelo vrijeme

Dodaj u košaricu

1 serija = 1 dionica

Iznos kupnje:

Brokerska provizija:

Provizija za prijenos:

Preporuka

Strong Buy

Rejting uspješnosti

DCF

288.69

ROE

0.37

ROA

0.16

P/S

3.3

P/B

4.14

Debt / Equity

0.69

Korporativne informacije

American Biogen Inc. is a global leader in biotechnology, engaged in scientific research and development of a wide range of medications for treatment of people with hematological, neuralgic and autoimmune diseases. As of today, Biogen is the third largest biotech company in the world. Company's financial gain as of 2015 equaled almost $ 3 billion. Scientific centers and hubs of Biogen Inc. are allocated in over 30 countries, where about 8,000 employees are engaged in various activities. One of the latest projects is Alprolix. It gained a worldwide recognition no more than a year after its first release in 2014 and was highly appraised by Medical Reviewers. Alprolix prevents most fatal bleedings and acts as a prophylactic agent for people with hemophilia.


Prijavite se kako biste primali ideje za ulaganje analitičara društva Freedom Finance

Jedanput tjedno slat ćemo Vam poruku e-pošte koja sadrži samo najrelevantnije i najvažnije informacije

Čestitamo!

Sada ćete uvijek biti svjesni u koje dionice je isplativije ulagati